EMA accepts application (MAA) for ixazomib to treat relapsed and/or refractory multiple myeloma- Takeda

Takeda Pharmaceutical Company Limited announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. On July 23, ixazomib was granted accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the EMA, a designation reserved for those medicines deemed to be of major public health interest and, in particular, therapeutic innovation.

The MAA submission was primarily based on the results of the first pre-specified interim analysis of the pivotal Phase III trial TOURMALINE-MM1, an international, randomized, double-blind, placebo controlled clinical trial of 722 patients designed to evaluate the superiority of ixazomib plus lenalidomide and dexamethasone over placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. Patients continue to be treated to progression in this trial and will be evaluated for long-term outcomes.

Comment: a New Drug Application for ixazomib to treat patients with relapsed and/or refractory multiple myeloma was filed with the FDA in July 2015.